For a long time, the pharmaceutical industry has operated within a sophisticated yet closed system. At its core lies a "franchise" model: companies invest heavily in research and development, endure lengthy processes, and undergo rigorous regulatory scrutiny, ultimately securing exclusive sales rights for an innovative drug within a limited patent period.

During this period, high pricing aims to recoup costs and generate profits. However, once the patent expires, generic drugs flood the market like a tide, swiftly eroding the pricing power and market share of the original drug—a phenomenon famously known as the "patent cliff."

This model has driven the industry's brilliance but has also planted the seeds of its constraints.

First, drug development itself is a highly uncertain and difficult-to-scale "art." Each new drug is like solving a unique biological puzzle, with the success of one drug rarely replicable in the next. The result is that pharmaceutical R&D output does not linearly correlate with investment; instead, it resembles spending vast sums to buy more "lottery tickets."

Second, to mitigate this uncertainty and pursue higher returns, the industry has increasingly focused on "precision medicine" over the past two decades—developing extremely expensive targeted therapies for rare diseases or specific patient populations with particular genetic mutations (such as gene therapies costing millions of dollars). While scientific breakthroughs have been achieved, the limited patient numbers cap market potential, and the exorbitant pricing continues to strain the affordability of healthcare systems worldwide.

At a deeper level, an invisible "wall" persists between the industry and its end-users—the patients. Pharmaceutical companies engage with doctors, hospitals, and insurance providers rather than directly with consumers. This "risk-averse" culture extends to communication, keeping pharmaceutical executives largely out of the public eye and contributing to an industry image that is often perceived as mysterious and frequently criticized for drug pricing issues.

In stark contrast, tech companies and their star founders have built strong brand affinity through direct communication with users. This wall, while protecting the industry, has also caused it to miss opportunities to build direct user relationships and brand loyalty.

Consequently, capital markets have grown accustomed to valuing pharmaceutical companies using a cautious formula: discounting future cash flows within the patent period while subtracting risks associated with R&D failures and generic competition. This explains why many industry giants, with revenues comparable to Eli Lilly, have long seen their market capitalizations hover around $200 billion.

A trillion-dollar valuation seemed like an unattainable ceiling.

The soaring market capitalization of Eli Lilly is primarily driven by its GLP-1 drug (tirzepatide). However, the disruption it brings extends far beyond the popularity of a mere "weight-loss miracle drug." At its core, GLP-1 has shattered several fundamental assumptions of the traditional pharmaceutical model.

Ricks offered a metaphor: the traditional model is like mining for rare minerals with increasingly precise tools (targeted therapies), but the target veins are becoming narrower and narrower (specific patient groups). In contrast, Eli Lilly’s new approach is akin to "blasting open the entire mountain range."

Eli Lilly views obesity as a "master switch" driving dozens of chronic diseases—from diabetes to cardiovascular conditions and even certain inflammatory diseases. By intervening in this upstream and widespread root cause, the drug can simultaneously address an unprecedented, massive potential market, directly targeting hundreds of millions of obese and overweight individuals worldwide.

This idea fundamentally reshapes the dimensions of value calculation. A simple yet powerful narrative has gained traction in the capital markets: Eli Lilly’s value is proportional to the total amount of excess global calories it eliminates. Ricks mentioned in the podcast that patients taking Lilly’s drugs reduce their daily calorie intake by an average of around 800 calories. This provides investors with a quantifiable and highly imaginative model.

When a drug no longer targets tens of thousands of patients but hundreds of millions of consumers, its valuation logic begins to diverge from the traditional pharmaceutical framework, aligning more closely with that of tech and consumer giants.

The more critical innovation, however, lies on the commercial front. GLP-1 drugs exhibit an unprecedented characteristic: clear demand and accessible payment thresholds. Patients do not require complex diagnoses to recognize their needs (obesity), and the monthly cost of several hundred dollars, while substantial, falls within the "within reach" range of middle-class self-pay options. This has spurred a revolutionary "direct-to-consumer" model.

Eli Lilly quickly launched its online pharmacy, LillyDirect, where patients can consult, receive prescriptions, and purchase medication directly online, completing payments with credit cards. This is no longer traditional pharmaceutical sales but an experience infinitely closer to that of Apple or Netflix—direct, simple, and user-centric.

Through GLP-1, Eli Lilly has inadvertently sketched a blueprint for a "new kind of pharmaceutical company." At the heart of this blueprint is a logic borrowed from tech companies: building a "flywheel effect."

By adopting a direct-to-consumer (DTC) model, Lilly has gained highly engaged users, stable cash flow, and, most importantly, user data and direct relationships. This is no longer a one-time drug transaction but a continuous healthcare service subscription. Wall Street has already begun reevaluating Lilly through the lens of a "subscription business," focusing on user retention and lifetime value.

A trillion-dollar market capitalization is not just an honor; it is a powerful weapon. It means Lilly can raise capital—whether through equity or debt—at significantly lower costs than its competitors, granting it an overwhelming advantage in the R&D arms race.

Abundant and "cheap" capital allows Lilly to dare to invest in areas that were previously abandoned due to unsustainable economic models, such as preventing Alzheimer's disease. Ricks revealed that they are considering shifting from traditionally sequential clinical trials to conducting them in parallel to accelerate development at an extreme pace. This strategy of "buying time with money" poses a dimensional threat to cash-constrained rivals.

Breakthrough drugs—whether preventive therapies for broader populations or treatments for other chronic diseases—can be rapidly brought to market through the already established DTC platform, further consolidating the user ecosystem and creating a cycle where "the strong get stronger."

Lilly's goal is no longer merely to treat existing diseases but to manage users' long-term health by intervening in upstream risk factors. This is precisely the ambition behind what Ricks calls "creating franchise value that extends beyond the patent cycle."

Lilly's success is not merely an inspiration for the rest of the pharmaceutical industry; it is also a mirror reflecting potential crises. The curtain has risen on an era of "asymmetric warfare."

Companies with blockbuster drugs like GLP-1 or the ability to pivot quickly to a DTC model will have the opportunity to replicate Lilly's flywheel, attract capital favor, and enter a fast lane of development. For companies still heavily reliant on traditional specialty drug models, with pipelines concentrated in narrow indications and isolated from end-users, the challenges will be unprecedented. The shorter links between pharmaceutical companies, tech platforms, and consumers may reshape the direction of value flow.

Of course, the road ahead is not without obstacles. The long-term safety of GLP-1 drugs, equity of access, and their ultimate impact on healthcare systems remain unresolved issues. Lilly's flywheel has only just begun to spin, and the key test will be whether it can consistently find the next "explosive point."

Returning to the scene of that tech podcast, why did Ricks choose to tell Lilly's story there? The answer is self-evident. He was not merely promoting a drug but announcing the birth of a new identity.

With a trillion-dollar market cap, Eli Lilly is no longer content to play the role of a traditional "pharmaceutical giant." It is attempting to press the industry's "reset" button, infusing the user-centric, speed-driven, and scale-oriented logic of the tech sector into the century-old body of pharmaceuticals. The core of this path lies in shifting from one-time battles against diseases to the continuous management of population health, and from selling compounds through intermediaries to directly providing health solutions to users.

The golden age of the pharmaceutical industry may not lie in the past, reliant on a handful of "blockbuster" drugs, but may well be dawning in this new era—one that dares to "blast open mountain ranges," directly serves hundreds of millions of users, and learns to think and grow like a tech company.